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ORIGINAL ARTICLE
JAK/STAT pathway inhibition overcomes IL7-induced
glucocorticoid resistance in a subset of human T-cell acute
lymphoblastic leukemias
C Delgado-Martin1,8, LK Meyer1,8, BJ Huang1, KA Shimano1, MS Zinter1, JV Nguyen1, GA Smith2, J Taunton2, SS Winter3, JR Roderick4,
MA Kelliher4, TM Horton5, BL Wood6, DT Teachey7 and ML Hermiston1
While outcomes for children with T-cell acute lymphoblastic leukemia (T-ALL) have improved dramatically, survival rates for patients
with relapsed/refractory disease remain dismal. Prior studies indicate that glucocorticoid (GC) resistance is more common than
resistance to other chemotherapies at relapse. In addition, failure to clear peripheral blasts during a prednisone prophase correlates
with an elevated risk of relapse in newly diagnosed patients. Here we show that intrinsic GC resistance is present at diagnosis in
early thymic precursor (ETP) T-ALLs as well as in a subset of non-ETP T-ALLs. GC-resistant non-ETP T-ALLs are characterized by
strong induction of JAK/STAT signaling in response to interleukin-7 (IL7) stimulation. Removing IL7 or inhibiting JAK/STAT signaling
sensitizes these T-ALLs, and a subset of ETP T-ALLs, to GCs. The combination of the GC dexamethasone and the JAK1/2 inhibitor
ruxolitinib altered the balance between pro- and anti-apoptotic factors in samples with IL7-dependent GC resistance, but not in
samples with IL7-independent GC resistance. Together, these data suggest that the addition of ruxolitinib or other inhibitors of IL7
receptor/JAK/STAT signaling may enhance the efﬁcacy of GCs in a biologically deﬁned subset of T-ALL.
Leukemia advance online publication, 30 May 2017; doi:10.1038/leu.2017.136
INTRODUCTION
T-cell acute lymphoblastic leukemia (T-ALL) arises from malignant
transformation of T-cell progenitors in the thymus.1 Intensiﬁed
therapy has dramatically improved survival for pediatric patients.2
However, outcomes for patients with relapsed or refractory T-ALL
remain dismal, with 5-year survival rates o10%.3 Unfortunately,
biomarkers of high-risk disease that might facilitate rational
therapeutic approaches that could be introduced early in therapy
are limited.4 Importantly, newly diagnosed patients that have
positive minimal residual disease (MRD) after initial therapy or that
fail to rapidly clear peripheral leukemic blasts during a prednisone
prophase have poorer outcomes.5,6 These data suggest that
intrinsic variability in sensitivity to chemotherapy and speciﬁcally
to glucocorticoids (GCs) exists at diagnosis. The observation that
GC resistance is commonly present at relapse7 and is more
frequent than is resistance to other drugs8 further supports this
idea and suggests that enhancing GC sensitivity in high-risk
patients early in therapy could have therapeutic beneﬁt.
GCs bind to the cytoplasmic GC receptor (GR) to form a complex
that translocates to the nucleus, where it regulates genes
implicated in diverse cellular processes including cell cycle arrest
and apoptosis.9,10 Insights into the mechanistic basis of GC
resistance in T-ALL are limited, and this is a barrier to
implementing rational therapeutic strategies for preventing or
overcoming it. Whereas alterations in GR function are a frequent
cause of GC resistance in T-ALL cell lines, similar abnormalities are
rare in patients.11,12 Leukemogenic events such as AKT
hyperactivation13 and Ikzf1 mutations14 have been implicated in
GC resistance in a subset of patients. Addition of interleukin-7 (IL7)
has also been shown to induce GC resistance in vitro in a subset of
samples.15 However, it is uncertain how these ﬁndings might be
translated into actionable therapeutic interventions.
The genetic heterogeneity of T-ALL has precluded the use of
genetic alterations for risk-based stratiﬁcation. We reasoned that
these diverse genetic lesions might converge on a more limited
set of biochemical abnormalities that could be used to identify
subsets of T-ALLs that share common mechanisms of chemother-
apy resistance. We tested this hypothesis by assessing drug
responses in vitro using phosphoﬂow cytometry in primary T-ALL
cells. Here, we show that intrinsic GC resistance is a hallmark of
T-ALLs arising at the early thymic precursor (ETP) stage and also
characterizes a subset of non-ETP T-ALLs. GC-resistant non-ETP
T-ALLs can be identiﬁed by augmented JAK/STAT signaling in
response to IL7 stimulation. Removing IL7 from the media
sensitizes these samples, and a subset of ETP T-ALLs, to GCs, but
not to other chemotherapies. Interestingly, only 4 of the 32
samples (12.5%) used in this study had mutations in the IL7
receptor (IL7R)/JAK/STAT pathway, suggesting that IL7-induced GC
resistance in this subset of T-ALL is independent of genetic drivers
of pathway activity and instead reﬂects a shared biologic property
that can be functionally deﬁned. The addition of the clinically
available JAK1/2 inhibitor ruxolitinib or newly developed JAK3
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inhibitor reversed intrinsic GC resistance. Together, these studies
support the use of JAK inhibitors to increase the efﬁcacy of GCs in
a biologically deﬁned subset of T-ALL patients.
MATERIALS AND METHODS
Patient samples and patient derived xenografts
Diagnostic bone marrow samples were obtained from sources indicated in
Supplementary Table 1. Informed consent for use of diagnostic specimens
for future research was obtained from patients or their guardians at the
time of sample collection, according to the Declaration of Helsinki, the
National Cancer Institute, and institutional review boards of participating
sites. The Institutional Animal Care and Use Committee approved animal
studies. Characteristics of patient derived xenografts (PDXs) are listed in
Supplementary Table 1. ETP status was deﬁned in the COG central
reference laboratory as previously described.4 PDXs were established by
injecting 1.5 to 2.5 x 106 cells intravenously into non-obese diabetic/severe
combined immunodeﬁcient NOD/SCID/Il2rgtm1wjl/SzJ (NSG) mice as pre-
viously described.16 Engraftment was determined by ﬂow cytometric
analysis of peripheral blood using anti-human CD45 antibodies. PDX
samples were used between passages 1 and 3 and evaluated at each
passage for ﬁdelity of cell surface markers, biochemical signatures, and
drug responsiveness.
Drug treatment and phosphoﬂow cytometry
Cells were thawed and rested 1 h at 37 °C in complete media (RPMI, 10%
FBS, 1% penicillin/streptomycin, 1% Glutamax (ThermoFisher, Waltham,
MA, USA)). 106 cells/ml were cultured in a 96-well plate with vehicle
(DMSO) or drug (araC, dexamethasone, etoposide, methotrexate, vorino-
stat (Sigma-Aldrich, St Louis, MO, USA), vincristine (Hospira, Lake Forest, IL,
USA), ruxolitinib and MK2206 (Selleck, Houston, TX, USA) and/or a newly
developed JAK3 inhibitor (JAK3i)17). Since spontaneous cell death is
common with in vitro culture of T-ALL samples, media was supplemented
with 25 ng/ml IL7 (Peprotech, Rocky Hill, NJ, USA), a cytokine known to
inhibit spontaneous apoptosis in T-ALL,18 unless otherwise indicated. Cells
were collected at 48 h and ﬂow cytometry performed as previously
described19 using a FacsVerse ﬂow cytometer (BD Biosciences, San Jose,
CA, USA). Antisera included anti-human CD7, activated caspase-3,
phospho-STAT5 (pSTAT5), phospho-Akt (pAkt) (Cat# 564019, 560627,
612599 and 560404, BD Biosciences), CD45, IL7R (Cat# 25-0459 and 20-
1278, Tonbo Biosciences, San Diego, CA, USA), BIM, GR (Cat# 2933 and
12041, Cell Signaling, Danver, MA, USA) and BCL2 (Cat# MHBCL04,
ThermoFisher). The frequency of viable Hoechst (ThermoFisher, Ashland,
OR, USA) or active caspase-3 negative cells in the CD7-positive gate was
determined using FlowJoV9.8.2 (TreeStar, Ashland, OR, USA). For phospho-
ﬂow studies, only viable CD7-positive cells were analyzed.
BH3 proﬁling
Apoptotic priming was measured as the depletion of intracellular
cytochrome C using ﬂow cytometry-based BH3 proﬁling as described by
Ryan et al.19 Brieﬂy, 106 cells/ml in complete media containing 25 ng/ml
IL7 were treated with vehicle, 1 μM dexamethasone and/or 500 nM
ruxolitinib for 16 h, permeabilized with digitonin (Sigma-Aldrich),
exposed to 100 nM BIM BH3 peptide (New England Biosciences, Ipswich,
MA, USA) or 1 μM ABT-199 (ApexBio, Houston, TX, USA) for 1 h, ﬁxed with
4% paraformaldehyde, stained with anti-cytochrome c antibody (Cat#
558709, BD Biosciences), and subjected to ﬂow cytometry. Cells treated
with DMSO and alamethicin (Alfa Aesar, Haverhill, MA, USA) were used as
negative and positive controls respectively. For each condition, the
percentage of cytochrome c depletion was calculated based on the
release of cytochrome c in the DMSO (0% loss) and alamethicin (100% loss)
controls and then normalized to vehicle treated cells.
Statistical analysis
Statistical analyses, as deﬁned in each ﬁgure legend, were performed using
Prism V5.0 (GraphPad, La Jolla, CA, USA).
Additional information is available in Supplementary Methods.
RESULTS
Intrinsic GC sensitivity identiﬁes distinct T-ALL subsets
Previous studies demonstrated that GC resistance in diagnostic
T-ALL samples in vitro correlated with poor response to upfront GC
treatment.20–22 To ask whether this in vitro resistance is also
associated with failure to eradicate circulating blasts by the end of
the induction phase of therapy, we exposed diagnostic samples
obtained from patients treated on the COG protocol AALL0434 to
vehicle control or dexamethasone and measured the percentage
of viable cells 48 h later. Whereas leukemic blasts from patients
with detectable MRD (MRD+) were uniformly resistant to GCs, cells
from most MRD- patients were GC sensitive (Supplementary
Figure S1).
Many PDX models accurately recapitulate the clinical features of
the cancers from which they were derived.23,24 To obtain sufﬁcient
numbers of primary blasts for detailed mechanistic studies, we
employed this model system to expand 22 non-ETP and 10 ETP
T-ALL samples derived from newly diagnosed pediatric T-ALL
patients in NSG mice (Supplementary Table 1). In vitro exposure to
dexamethasone reduced the viability of all ETP T-ALL byo50%. In
contrast, the 22 non-ETP T-ALLs exhibited signiﬁcant variability in
GC sensitivity, with 5 being highly GC sensitive and 8 others
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Figure 1. ETP T-ALL samples are intrinsically more resistant to GCs than are non-ETP T-ALLs. PDX samples were thawed, rested 1 h, and then
exposed to vehicle or dexamethasone (Dex). Cells were stained with Hoechst dye at 48 h and subjected to ﬂow cytometry. (a) Percentage of
viable cells, relative to vehicle, of non-ETP T-ALL (circles, n= 22) and ETP T-ALL (squares, n= 10) PDX samples after 48 h treatment with 2.5 μM
dexamethasone. Data were analyzed using the parametric unpaired t-test with Welch’s correction (unequal variances). ***Po0.001.
(b) Percentage of viable cells, relative to vehicle, of representative samples of ETP T-ALLs (n= 8) and non-ETP T-ALLs (n= 10) exposed to
increasing doses of dexamethasone (0, 100, 500 nM and 2.5 μM) for 48 h. Data are represented as mean± s.e.m. of the biological replicates.
Error bars show s.e.m.
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showing ETP-like resistance to dexamethasone-induced apoptosis
(Figure 1a). Higher concentrations of dexamethasone failed to
further affect viability, suggesting that individual leukemias have
intrinsic set points for GC sensitivity (Figure 1b). These differences
in GC sensitivity are not due to variable levels of GR expression
(Supplementary Figure S2).
IL7 mediates GC resistance in a subset of T-ALL
We previously demonstrated that ETP T-ALLs and a subset of non-
ETP T-ALLs activate downstream signaling molecules in response
to IL7 stimulation regardless of the presence of an IL7R pathway
mutation.16 Furthermore, the JAK1/2 inhibitor ruxolitinib inhibits
this response and prevents leukemic outgrowth of ETP T-ALLs in a
PDX model.16 To determine whether IL7 modulates intrinsic GC
sensitivity in T-ALL blasts, we treated PDX samples with vehicle or
dexamethasone in the presence or absence of IL7. As expected
given the pro-survival function of IL7,25,26 T-ALL cell viability was
signiﬁcantly reduced in many samples cultured in the absence of
IL7 (Supplementary Figure S3). A subset of ETPs remained GC
resistant in the absence of IL7, suggesting IL7-independent
mechanisms of GC resistance in these leukemias. Intriguingly,
however, the remaining leukemias exhibited greatly enhanced GC
sensitivity upon removal of IL7 (referred to henceforth as ‘IL7-
dependent GC-resistant’) (Figure 2a). Consistent with our prior
ﬁnding,16 sequencing of IL7R, JAK1, JAK3, STAT5A, STAT5B and
DNM2 revealed that IL7-dependent GC resistance is independent
of the presence of an activating IL7R/JAK/STAT pathway mutation
(Supplementary Table 1).
The protective effect of IL7 is drug-speciﬁc
Since chemotherapy regimens for ALL consist of multiple drugs,27
we investigated if the ability of IL7 to protect T-ALL cells from
chemotherapy-induced death was GC speciﬁc or reﬂective of pan-
chemotherapy resistance. To better understand the mechanistic
basis for this protective effect of IL7, we exposed non-ETP and IL7-
dependent GC-resistant ETP T-ALL PDX samples to conventional
chemotherapeutic agents in the presence of IL7. IL7 failed to
protect them against death induced by cytosine arabinoside,
methotrexate, vincristine, or etoposide (Figures 2b and c). As
expected, IL7 protected both non-ETP and ETP T-ALLs from death
induced by dexamethasone. Interestingly, IL7 treatment also
antagonized the ability of vorinostat, a histone deacetylase
(HDAC) inhibitor, to kill T-ALL cells in vitro (Figures 2b and c).
IL7 responsiveness distinguishes a subset of GC-resistant non-ETP
T-ALLs
To determine if IL7 responsiveness might serve as a biomarker to
distinguish GC sensitive and GC-resistant non-ETP T-ALLs, we
stimulated non-ETP T-ALL PDX samples with IL7 and measured
changes in phosphorylated STAT5 (pSTAT5) levels (Supplemen-
tary Figure S4A). These studies indicate that non-ETP T-ALLs can
be broadly assigned to one of three groups based on their IL7
response: (1) a highly responsive subset with pSTAT5 induction
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Figure 2. IL7 deprivation sensitizes a subset of T-ALL samples to
dexamethasone-induced cell death. (a) Percentage of viable cells,
relative to vehicle, after 48 h of treatment with 2.5 μM dexametha-
sone in the presence (ﬁlled shapes) or absence (empty shapes) of
25 ng/ml IL7. Dashed line indicates 75% relative viability. Non-ETP
T-ALL (n= 22), ETP T-ALL (n= 10). (b) Non-ETP and (c) ETP PDX
samples were subjected to 48 h treatment with 2.5 μM dexametha-
sone, 125 ng/ml AraC, 500 nM etoposide (etop), 250 nM vorinostat
(vor), 2.5 μM methotrexate (MTX), or 5 μM vincristine (VCR) in the
presence (gray) or absence (white) of 25 ng/ml IL7 and processed as
above (n= 4 to 22). Paired T-test (Wilcoxon—non normal distribu-
tion—in the case of ETPs) was used to evaluate statistical
signiﬁcance. *Po0.05; **Po0.01; ***Po0.001. Data are represented
as mean± s.e.m. of the biological replicates. Error bars show s.e.m.
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similar to ETP T-ALL samples (responders; n= 10); (2) a subset with
a smaller biphasic shift in pSTAT5 (partial responders; n= 7); and
(3) a subset with no response (non-responders; n= 5) (Figure 3a).
We next asked if IL7 responsiveness predicts GC sensitivity in non-
ETP T-ALLs by plotting the GC sensitivity of these three subsets
according to the ability of IL7 to increase pSTAT5 levels
(Figure 3b). The non-ETP responder subset displayed similar
intrinsic resistance to GC-induced death as did IL7-dependent GC-
resistant ETP T-ALLs, while the non-responder subset was most GC
sensitive. Partial responders exhibited an intermediate phenotype.
Removing IL7 from the media markedly enhanced cell death in
the responder and partial responder groups but had no impact on
the non-responder group (Figure 3b). Moreover, stratifying non-
ETP T-ALL samples according to their IL7 response and evaluating
their sensitivity to the drugs tested in Figure 2 showed that
responders behaved similarly to ETP T-ALLs, with IL7-dependent
resistance to dexamethasone and vorinostat, but that IL7 had no
effect on drug sensitivity for non-responders (Supplementary
Figure S4B).
We previously reported that IL7 responsiveness correlated with
IL7R expression in ETP and non-ETP T-ALLs.16 Similarly, plotting
the difference in pSTAT5 levels between basal and IL7-stimulated
cells (ΔpSTAT5) against IL7R expression in this extended panel of
T-ALLs conﬁrmed a signiﬁcant positive relationship between these
parameters (Supplementary Figure S4C, right). There was also a
positive correlation between ΔpSTAT5 and sensitivity to GCs in the
presence of IL7 (Supplementary Figure S4C, left). Together, these
data indicate that intrinsic GC sensitivity at diagnosis is modulated
by IL7 in a subset of T-ALLS.
Inhibition of JAK/STAT signaling sensitizes IL7-dependent samples
to dexamethasone
IL7 exerts pro-survival effects by activating JAK1, JAK3 and STAT5
downstream of the IL7R.28 We hypothesized that pharmacological
inhibition of JAK/STAT signaling would mimic the effects of
culturing cells in IL7-deﬁcient media. Ruxolitinib is an FDA
approved JAK1/2 inhibitor currently in clinical trials in pediatric
patients.29,30 We ﬁrst determined that ruxolitinib blocked IL7-
induced STAT5 phosphorylation for 48 h in cultured T-ALL cells
(Figures 4a and b). We next exposed T-ALL PDX samples to vehicle,
ruxolitinib alone, dexamethasone alone, or dexamethasone plus
ruxolitinib. Ruxolitinib alone had only modest effects on cell viability
in vitro (Figure 4c). However, combining ruxolitinib with dexametha-
sone enhanced cell death in the IL7-dependent ETP and non-ETP
responder and partial responder samples, but not the non-
responder samples (Figure 4c). Importantly, ruxolitinib increased
GC sensitivity in the responder non-ETP T-ALL samples to levels seen
in intrinsically GC sensitive T-ALLs (Supplementary Figure S5).
Because JAK3 has also been implicated in IL7R signaling in T-
cells,28 we tested a newly developed JAK3 inhibitor (JAK3i).17
JAK3i inhibited IL7-mediated pSTAT5 induction in a dose-
dependent manner (Supplementary Figure S6A). Similar to
ruxolitinib, JAK3i had only a modest effect as a single agent, but
induced GC sensitivity in samples previously shown to use IL7 to
resist GCs (Supplementary Figure S6C). These results suggest that
both JAK1 and JAK3 are required for functional IL7R signaling and
that inhibiting either protein is sufﬁcient to abrogate the
protective effect of IL7.
IL7
Veh
Figure 3. IL7 responsiveness distinguishes non-ETP T-ALL samples
and correlates with GC sensitivity. (a) PDX samples were thawed,
rested 1 h, and then exposed to vehicle or 100 ng/ml IL7 for 15 min.
STAT5 phosphorylation (pSTAT5) was analyzed by phosphoﬂow
cytometry. Non-ETPs were placed into subsets based upon their IL7
responsiveness. Top depicts representative histograms of pSTAT5 in
the basal state (shaded) and after 15 min of stimulation with 100 ng/
ml IL7 for each subset (empty line). Bottom shows quantitation of
pSTAT5 median ﬂuorescence intensity (MFI) in the basal state and in
response to IL7 exposure for each sample. (b) PDX samples were
exposed to vehicle or 2.5 μM dexamethasone for 48 h in the
presence (black circles) or absence (gray squares) of 25 ng/ml of
IL7. Percentage of viable cells, relative to vehicle, for each of the
subgroups (Responders, n= 10, partial responders, n= 7, non-
responders, n= 5, and ETPs, n= 6) was measured by quantiﬁcation
of the Hoechst-negative fraction using ﬂow cytometry. Paired T test
(Wilcoxon) was used to evaluate statistical signiﬁcance. *Po0.05,
**Po0.01. Data are represented as mean± s.e.m. of the biological
replicates. Error bars show s.e.m.
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The combination of dexamethasone and ruxolitinib alters the
balance between BCL2 and BIM
GCs exert their effects by inducing diverse transcriptional changes,
which include modulating the expression of many genes involved
in apoptosis. In particular, GCs have been described to down-
regulate the expression of pro-survival BCL2 and upregulate the
expression of pro-apoptotic BIM in lymphoblasts.9,10,31 IL7R
signaling affects expression of anti-apoptotic genes which induces
expression of pro-survival proteins including BCL2, among
others.32–34 To study potential molecular events that might
mediate IL7-dependent GC resistance, we compared BCL2 and
BIM protein expression between IL7-dependent GC-resistant ETP
and non-ETP leukemias, and IL7-independent GC-resistant ETP
samples exposed to vehicle, ruxolitinib alone, dexamethasone
alone, or dexamethasone plus ruxolitinib in the presence of IL7.
Gating on only viable (caspase-3 negative) cells (Supplementary
Figure S7A and B) after 48 h of drug exposure, we found that IL7-
independent GC-resistant ETPs had minimal changes in BCL2 or
BIM expression in any condition. In contrast, in IL7-dependent GC-
resistant leukemias, ruxolitinib treatment alone resulted in a
marked decrease in BCL2 protein expression relative to vehicle,
while cells surviving dexamethasone treatment alone had
elevated BCL2 expression. Addition of ruxolitinib to ruxolitinib
alone, dexamethasone abrogated the increase in BCL2 (Figure 5a).
Given this unexpected increase in BCL-2 expression induced by
dexamethasone treatment in the presence of IL7, we assessed
BCL-2 transcript levels under these conditions, further conﬁrming
this ﬁnding (Supplementary Figure 7A). Interestingly, dexametha-
sone resulted in a signiﬁcant increase in BIM expression, while
ruxolitinib had no effect alone or in combination with dexa-
methasone (Figure 5b).
To interrogate the functional consequences of these changes in
protein expression, we utilized dynamic BH3 proﬁling to assess the
intrinsic apoptotic potential, or ‘priming’, of cells under these
different conditions. We ﬁrst measured priming using a synthetic
peptide corresponding to the BIM BH3 domain, which antagonizes
all anti-apoptotic members of the BCL2 family of proteins.35 As a
single agent, ruxolitinib, but not dexamethasone, increased
apoptotic priming in IL7-dependent GC-resistant samples. Combi-
nation therapy further augmented apoptotic priming in these
leukemias, supporting their IL7-dependent, GC-resistant status.
(Figure 6a). Consistent with their IL7-independent GC-resistant
status, apoptotic priming was not affected in any treatment
conditions in these samples. To determine if differences in
apoptotic potential were attributable speciﬁcally to alterations in
BCL2 activity, consistent with the changes in protein expression
observed in Figure 5, we performed dynamic BH3 proﬁling using
the BCL2 antagonist ABT-199. Importantly, the proﬁle appeared
highly similar to that of the BIM BH3 peptide, suggesting that IL7-
associated differences in apoptotic potential are driven in large
part by a BCL2-dependent mechanism (Figure 6b).
Finally, we asked whether ABT-199 could mimic the ability of
ruxolitinib to induce GC sensitivity in IL7-dependent T-ALLs. Cells
were treated in the presence of IL7 with dexamethasone alone or
in combination with either ruxolitinib or ABT-199. Consistent with
our previous ﬁndings, both IL7-dependent and -independent
samples were dexamethasone resistant in the presence of IL7.
Whereas addition of ruxolitinib markedly and selectively
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Figure 4. Ruxolitinib blocks IL7R signaling and abrogates the protective effect of IL7 on GC activity. (a) pSTAT5 of a representative ETP T-ALL
PDX sample incubated with increasing doses (67.5, 125, 250, 500 and 1000 nM) of ruxolitinib (rux) and then stimulated with 100 ng/ml of IL7
for 15 min. (b) Representative histogram of pSTAT5 after 48 h of culture with vehicle (tinted line) or 500 nM ruxolitinib (empty line) in the
presence of 25 ng/ml IL7. (c) PDX samples (Responder n= 10, Partial n= 5, non-responder n= 4, ETP n= 6) were subjected to 48 h treatment
with vehicle, 2.5 μM dexamethasone, 500 nM ruxolitinib or the combination of dexamethasone and ruxolitinib in the presence of 25 ng/ml IL7.
Percentage of viable (Hoechst negative) cells relative to vehicle was quantiﬁed for each subset. Data are represented as mean± s.e.m. of the
biological replicates. Error bars show s.e.m.
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attenuated dexamethasone resistance in IL7-dependent GC-
resistant leukemias, ABT-199 had more modest effects
(Figure 6c). These data suggest that IL7-dependent dexametha-
sone resistance is partially due to changes in BCL2 activity.
To test the hypothesis that PI3K/AKT signaling might link IL7R
activation to dexamethasone resistance, we exposed IL7-
dependent GC-resistant leukemias to the AKT inhibitor MK2206,
alone and in combination with ruxolitinib and/or dexamethasone,
but observed little or no effect on T-ALL survival and apoptotic
priming (Supplementary Figure S8B and D). Although AKT
inhibition resulted in the downregulation of BCL2, in contrast to
the net effect of dexamethasone plus ruxolitinib on BCL2
expression, the combination of MK2206 with dexamethasone
was not sufﬁcient to counteract GC-induced upregulation of BCL2.
DISCUSSION
The goal of modern pediatric ALL therapy is to provide sufﬁcient
therapy to maximize cure while minimizing toxicity. Given that
most T-ALL relapses occur early and that salvage rates are dismal
following relapse,3 characterizing mechanisms of intrinsic or
acquired chemotherapy resistance are essential for improving
outcomes. Currently, the strongest predictors of outcome in T-ALL
are MRD and the initial response to GCs during induction
therapy.5,6 Previous reports demonstrate that in vitro drug
sensitivity correlates with in vivo clinical response.20–22 While
further studies are needed to deﬁne biomarkers of clinical
response and resistance to GC therapy, our data suggest that, at
least in vitro, differences in GC sensitivity are independent of GR
expression. Furthermore, we have identiﬁed a subset of diagnostic
T-ALL samples that is GC resistant in an IL7-dependent manner
and that can be sensitized to GCs with JAK inhibition. These
ﬁndings have important translational implications for considering
the addition of IL7R pathway inhibitors in a subset of patients.
Here we show that PDX samples derived from patients with ETP
T-ALL are more resistant to in vitro dexamethasone treatment than
are non-ETP T-ALL PDX samples. This is consistent with the
observation that ETP T-ALL patients frequently have positive MRD
at the end of induction,36–38 likely reﬂecting, at least in part,
intrinsic GC resistance. Similarly, non-malignant double negative
(DN) thymocytes, which give rise to ETP T-ALLs, are refractory to
GCs.39 This appears to be due to IL7-mediated upregulation of the
pro-survival factor BCL2,32 which is more highly expressed in DN
cells relative to other thymocyte populations.40,41 We have
identiﬁed highly consistent patterns of GC resistance, IL7
responsiveness, and high BCL2 expression across ETP T-ALL
samples,16 supporting the hypothesis that these leukemias retain
properties of the DN thymocytes from which they arise.
The genetic heterogeneity of T-ALL has precluded the
identiﬁcation of clinically relevant genetic subsets that are
amenable to therapeutic intervention. Despite this heterogeneity,
we reasoned that differences in sensitivity to chemotherapy might
result from a more limited set of changes in signal transduction
and response to environmental stimuli. Supporting this notion,
ETP T-ALLs were uniformly GC resistant while non-ETP T-ALLs were
much more heterogeneous. We could identify distinct subsets
within these non-ETP samples based upon their response to IL7
stimulation. Importantly, mutational analysis revealed that IL7-
dependent GC resistance is independent of the presence of
activating pathway mutations, suggesting that biochemical
analysis may be necessary for the identiﬁcation of distinct T-ALL
subsets that may carry prognostic and therapeutic signiﬁcance.
We speculate that a subset of T-ALLs may retain physiologic
dependence on IL7. IL7 is a well-established pro-survival factor
present in plasma and lymphopoietic niches42 that protects
normal thymocytes and T-ALL cells from spontaneous18,43,44 and
chemotherapy-induced apoptosis.15,45 Since lymphocyte deple-
tion results in increased IL7 production by stromal cells as a means
of restoring lymphocyte homeostasis,46–49 we hypothesize that
there may exist a positive feedback loop, whereby the majority of
leukemia cells are depleted in response to GCs, but those cells that
survive the initial exposure to GCs then encounter augmented
levels of IL7 in the microenvironment, which, in the case of
patients with IL7-induced GC resistance, could facilitate the
persistence of these cells. While prior work suggested that
elevated IL7R expression positively correlates with clinical
outcomes,18,50 we and others15,45,51 have found a negative
correlation between IL7R signaling and GC sensitivity. We expand
on this ﬁnding here by demonstrating a novel therapeutic strategy
to ameliorate this antagonistic relationship between IL7R signaling
and GC sensitivity.
We hypothesized that IL7-dependent dexamethasone resis-
tance could be overcome with inhibition of IL7R signaling. All
signaling initiated by IL7 requires phosphorylation of the IL7R by
constitutively associated JAK kinases, which in turn creates
docking sites that allow for the recruitment of effectors such as
STAT5 and PI3K.52 JAK inhibition would therefore prevent IL7-
induced activation of both pro-survival pathways. The JAK1/2
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Figure 5. Treatment with ruxolitinib and dexamethasone alters the balance between BCL2 and BIM. Representative PDX samples that either
need IL7 to survive GC-induced death (‘IL7-dependent’, n= 5) or that were GC-resistant (remained 475% viable) even in the absence of IL7
(‘IL7-independent’, n= 4), were treated for 48 h with vehicle, 2.5 μM dexamethasone, 500 nM ruxolitinib or the combination of both drugs in
IL7-containing media. Expression of BCL2 (a) and BIM (b) was determined for cells in the viable, active caspase-3 negative gate. One sample t-
test was used to evaluate statistical signiﬁcance. *Po0.05; **Po0.01. Data are represented as mean± s.e.m. of the biological replicates. Error
bars show s.e.m.
Inhibiting IL7 signaling overcomes steroid resistance
C Delgado-Martin et al
6
Leukemia (2017), 1 – 9
inhibitor ruxolitinib, an FDA approved agent that is well tolerated
in pediatric patients,30 prevents IL7R-dependent phosphorylation
of both AKT53,54 and STAT5.16 Pre-clinical studies of ruxolitinib
using in vivo models of mouse55 and human16 ETP-ALL demon-
strated an anti-leukemic effect. Importantly, as a single agent,
ruxolitinib did not induce complete remissions, suggesting a
cytostatic, rather than cytotoxic, effect. However, combination
with standard chemotherapy may potentiate the anti-leukemic
effect of these conventional therapies, as seen in Ph+ ALL.56 We
similarly observe in this panel of T-ALLs that, while ruxolitinib
alone is not cytotoxic in vitro in most samples, it is capable of
sensitizing cells to dexamethasone-induced apoptosis. A similar
effect was observed with JAK3i, providing evidence that both
JAK1 and JAK3 are required for effective IL7R signaling. Interest-
ingly, of the agents we tested, the protective effect of IL7 was
restricted to dexamethasone and vorinostat, agents that modulate
gene transcription. To our surprise, JAK inhibition did not
overcome GC resistance in some ETP T-ALLs, despite their strong
response to IL7 stimulation, suggesting that they utilize IL7-
independent means to resist GCs. Alternative therapeutic
strategies to improve GC efﬁcacy for this subset of patients would
be needed.
In normal thymocytes, IL7 mediates survival by inducing
expression of BCL2,32 among other pro-survival proteins.33,34
GCs are known to downregulate expression of BCL2,31,57 but here
we show that, in the IL7-dependent GC-resistant samples, the cells
that survive dexamethasone treatment show elevated levels of
BCL2. We hypothesize that this is an effect of IL7R signaling, and
demonstrate, using both protein expression and a functional
assay, that the effects of IL7R and GCs on BCL2 can be uncoupled
via inhibition of IL7R signaling. Speciﬁcally, we demonstrate that,
in IL7-dependent leukemias, the IL7-induced upregulation of BCL2
overcomes the GC-induced downregulation of BCL2, resulting in a
persistent anti-apoptotic state. We demonstrate the functional
signiﬁcance of this IL7 effect by showing that dexamethasone
increases the apoptotic potential of these cells, and speciﬁcally
decreases BCL2 activity, only in the absence of intact IL7R
signaling. The fact that the combination of dexamethasone with
ABT-199 failed to completely sensitize IL7-dependent samples to
GC-induced apoptosis might be explained by the activity of other
pro-survival proteins, such as MCL1 or BCL-XL,33,34 which have
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Figure 6. IL7R signaling prevents a dexamethasone-induced increase in apoptotic priming. (a) Apoptotic priming of IL7-dependent (n= 3) and
-independent (n= 3) samples treated for 16 h with vehicle, 1 μM dexamethasone, 500 nM ruxolitinib, or a combination of the two in IL7-
containing media, as assessed by depletion of intracellular cytochrome c following a 1-h exposure to 100 nM BIM BH3 peptide. % priming
values are normalized to the vehicle control condition. (b) Apoptotic priming of IL7-dependent and -independent samples following a 1-h
exposure to 1 μM ABT-199. % priming values are normalized to the vehicle control condition. (c) Cell viability of IL7-dependent and
-independent samples with the addition of 2.5 μM dexamethasone relative to vehicle, 500 nM ruxolitinib, or 200 nM ABT-199 alone. Data are
represented as mean± s.e.m. of the biological replicates. Error bars show s.e.m.
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similarly been shown to contribute to GC resistance. Additional
studies are needed to evaluate the role of these other key anti-
apoptotic mediators in GC resistance in T-ALL.
In conclusion, we identify biologically distinct groups of
pediatric T-ALLs that differ with respect to intrinsic GC sensitivity
in the presence of IL7 and demonstrate that this correlates with
STAT5 activation in response to IL7 stimulation. A prospective
analysis to conﬁrm the existence of these subsets is being
performed in the context of the current COG frontline trial
AALL1231. Our data suggest that individual T-ALL samples have
intrinsic differences in GC sensitivity, and show that this sensitivity
can be altered by environmental stimuli, such as IL7. Modulating
sensitivity to GCs with agents such as ruxolitinib or JAK3i in the
subset of patients with IL7-dependent GC resistance should be
explored as a means of facilitating a deeper, more durable
remission and as a way of ultimately improving outcomes.
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